Press Releases

03-27-2023	Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
03-13-2023	Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
03-09-2023	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
03-08-2023	Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
03-01-2023	Pliant Therapeutics to Participate in Upcoming Investor Events
02-07-2023	Pliant Therapeutics to Participate in Upcoming Investor Events
02-02-2023	Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
01-27-2023	Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01-25-2023	Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
01-24-2023	Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering